Westchester Capital Management Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 2.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 201,804 shares of the biopharmaceutical company’s stock after selling 4,444 shares during the period. Pfizer makes up 3.0% of Westchester Capital Management Inc.’s holdings, making the stock its 21st biggest holding. Westchester Capital Management Inc.’s holdings in Pfizer were worth $7,162,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Washington Trust Bank raised its holdings in shares of Pfizer by 3.2% during the fourth quarter. Washington Trust Bank now owns 66,841 shares of the biopharmaceutical company’s stock valued at $2,421,000 after purchasing an additional 2,043 shares during the period. Lynch & Associates IN raised its holdings in shares of Pfizer by 1.7% during the fourth quarter. Lynch & Associates IN now owns 185,128 shares of the biopharmaceutical company’s stock valued at $6,705,000 after purchasing an additional 3,124 shares during the period. QUANTRES ASSET MANAGEMENT Ltd raised its holdings in shares of Pfizer by 302.4% during the fourth quarter. QUANTRES ASSET MANAGEMENT Ltd now owns 33,800 shares of the biopharmaceutical company’s stock valued at $1,224,000 after purchasing an additional 25,400 shares during the period. First National Bank of Mount Dora Trust Investment Services raised its holdings in shares of Pfizer by 4.4% during the fourth quarter. First National Bank of Mount Dora Trust Investment Services now owns 142,887 shares of the biopharmaceutical company’s stock valued at $5,176,000 after purchasing an additional 6,024 shares during the period. Finally, Confluence Investment Management LLC raised its holdings in shares of Pfizer by 3.1% during the fourth quarter. Confluence Investment Management LLC now owns 2,403,747 shares of the biopharmaceutical company’s stock valued at $87,064,000 after purchasing an additional 71,754 shares during the period. Institutional investors and hedge funds own 69.45% of the company’s stock.
In other Pfizer news, Director W Don Cornwell sold 5,223 shares of the company’s stock in a transaction dated Monday, June 4th. The shares were sold at an average price of $36.40, for a total value of $190,117.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Laurie J. Olson sold 19,000 shares of the company’s stock in a transaction dated Wednesday, June 6th. The stock was sold at an average price of $36.45, for a total transaction of $692,550.00. Following the completion of the sale, the executive vice president now directly owns 98,644 shares of the company’s stock, valued at $3,595,573.80. The disclosure for this sale can be found here. Insiders sold a total of 156,535 shares of company stock valued at $5,647,222 over the last ninety days. 0.06% of the stock is currently owned by insiders.
PFE has been the topic of several research reports. Morningstar set a $43.50 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, May 2nd. JPMorgan Chase & Co. restated a “buy” rating and issued a $42.00 target price on shares of Pfizer in a report on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Wednesday, April 11th. BMO Capital Markets set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, April 2nd. Finally, Morgan Stanley restated a “buy” rating and issued a $43.00 target price on shares of Pfizer in a report on Monday, June 11th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $40.32.
Shares of PFE stock opened at $36.35 on Thursday. Pfizer Inc. has a 52-week low of $32.32 and a 52-week high of $39.43. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $216.27 billion, a price-to-earnings ratio of 13.72, a PEG ratio of 1.80 and a beta of 0.93.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.03. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business had revenue of $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the prior year, the firm posted $0.69 EPS. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Thursday, August 2nd. Pfizer’s payout ratio is 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.